Tolerogenicity of resting and activated B cells by unknown
Tolerogenicity  of Resting  and Activated  B  Cells 
By Kathleen M.  Gilbert and William O. Weigle 
From the Department of Immunology,  The Scripps Research Institute,  La Jolla, 
California  92037 
Summary 
Antigen presentation by resting splenic B cells has been shown previously to induce T  helper 
I cell (Thl) anergy. In contrast to expectations,  it was found here that B cells treated with F(ab')2 
goat anti-mouse immunoglobulin (IgM) for 24 or 48 h  also presented antigen (Ag) to Thl 
cells in a manner that induced dramatic Ag-specific proliferative inactivation. The tolerogenicity 
of the anti-Ig-treated B cells was consistent with the observation that these B cells were only 
slightly more efficient than resting B cells in stimulating human gamma globulin (HGG)-induced 
proliferation of HGG-specific Thl cells in primary cultures. The activated B cells were, however, 
more efficient than resting B cells in stimulating a primary mixed leukocyte reaction, and exhibited 
increased expression of major histocompatibility complex class II molecules, RL388  Ag and 
transferrin receptor. In addition, unlike resting B cells, which expressed little detectable B7, anti- 
Ig-treated B cells expressed high levels of B7.  The functional capacity of the B7 expressed on 
the activated B cells was demonstrated by the fact that the Ag-presenting capacity of these B 
cells was inhibited by the addition to culture of CTLA4Ig, a soluble receptor for B7. It is unlikely 
that the tolerogenicity of the activated B cells was due to an inability of the Thl cells to respond 
to B7 signals;  the Thl clones used in the experiments, unlike the Th2 clones tested, expressed 
CD28, the ligand for B7. In addition, anti-CD28 monoclonal antibody inhibited the induction 
of Thl cell anergy when added to cultures of Thl cells and Ag-pulsed fixed antigen-presenting 
cells. Taken together, the results indicate that B cells, even when activated, do not satisfy the 
costimulatory requirements of the Thl cells used here, and therefore can present Ag in a tolerogenic 
fashion to Thl cells. The costimulator deficiency of activated B cells may reflect an inadequacy 
in the level of B7 expressed or a lack of some other molecule. 
ntigen-specific inactivation of Thl cells can be induced 
in vitro by exposing the Thl cells to Ag presented by 
APCs that lack costimulatory molecules. Tolerogenic APCs 
often consist of spleen cells that have been pulsed with Ag 
and then chemically fixed (1, 2). However, there is also evi- 
dence showing that nonfixed resting B cells are capable of 
presenting Ag to T cells in a tolerogenic fashion. It has been 
noted in several systems that lightly irradiated resting B cells 
are either ineffective or inferior APCs for the initiation of 
primary Thl responses to mitogens or antigens (3-6). Using 
Thl clones specific for human gamma globulin (HGG) 1, it 
was found that B cell inefficiency as APCs was associated with 
antigen-specific inactivation: Thl cells exposed to HGG and 
lightly irradiated splenic B cells in primary cultures were un- 
able to proliferate to HGG and immunogenic APCs in sec- 
ondary cultures (7). In vivo, the role of B cells as tolerogenic 
APCs has been demonstrated in mice by using Fab fragments 
1 Abbreviations used in this paper: CM, conditioned  medium; FAPC, fixed 
antigen presenting  cells; FCF, flow  cytofluorimetric;  FH, Ficoll-Hypaque; 
FI, fluorescein;  HGG, human gamma globulin; IF, immunofluorescent; 
TfR, transferrin receptor. 
of rabbit  anti-mouse IgD  to induce tolerance specific for 
nonimmune rabbit Ig (8). Tolerance to rabbit Ig was appar- 
ently dependent on antigen presentation by B cells, since in- 
travenous injection of soluble Fab nonimmune rabbit Ig, which 
is not targeted to B cells, resulted in a lower degree of toler- 
ance, especially at lower doses. It has also been demonstrated 
that injection of a population of spleen cells consisting pri- 
marily of small resting B cells induced hyporesponsiveness 
to MHC alloantigen (9), and to the male-specific antigen H-Y 
in mice (10). Presumably, the tolerogenicity of resting B cells 
is due to the fact that although resting B cells can present 
Ag in conjunction with MHC class II molecules, they lack 
the costimulatory molecules required to fully activate T cells. 
Although the identity of the costimulator molecule whose 
absence may be associated with B cell tolerogenicity is not 
known, a good candidate for such a molecule is the B7/BB-1 
antigen. B7 is not expressed on resting B cells, but is ex- 
pressed on dendritic cells (11) which are particularly potent 
accessory cells for T  cells (12). The B7 molecule on APCs 
binds both CTLA-4, which is expressed on activated T cells 
(13), and CD28, which is expressed on >80% of resting pe- 
ripheral CD4 + T  cells  (14).  Ligation of CD28  initiates a 
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that initiated by TCtL ligation (for a review see reference 15), 
and costimulates proliferation and IL-2 production by normal 
T  cells in conjunction with antigens or mitogens (16,  17). 
In terms of Thl cells specifically, it has been shown that anti- 
CD28  mAb  costimulates proliferation of Thl cells to Ag- 
pulsed  fixed  spleen  cells,  and  interferes with  Thl  cell in- 
activation in  these cultures  (18).  Thus,  it appears  that  B7 
ligation of CD28 on Thl cells has the capacity to costimu- 
late Thl  cell activation. 
The potential for B  cell-mediated ligation  of CD28  on 
Thl cells is enhanced in activated B  cells through  the up- 
regulation of B7. The increased B7 expression on activated 
B cells (19-21) appears to correlate with increases in certain 
aspects of B cell Ag presentation. Activated B cells have been 
shown to be more e~cient than resting B cells in promoting 
a MLR (22), and in costimulating Ag- or mitogen-induced 
T cell proliferation (23-26). Aside from B7, a number of other 
B lineage-associated and restricted Ags (e.g., CDw40, CD23, 
and CD25) are upregulated on activated B cells (27-29). In- 
creased expression of MHC class II molecules is also observed 
on activated B cells (30). Because of the increased expression 
of B7 and other accessory molecules and activation Ags on 
stimulated  as compared to resting B  cells, it seemed likely 
that activated B cells would, unlike resting B cells, present 
Ag to Thl cells in an immunogenic rather than a tolerogenic 
fashion. This study was conducted to test this point. In con- 
trast to our expectations, activated B cells retained their ability 
to present  Ag in  a manner  that  led  to Thl  inactivation. 
Materials and Methods 
Animals.  4-5-wk-old male A/J mice were purchased from the 
National Cancer Institute (Bethesda, MD). Experiments were per- 
formed by using 8-12-wk-old mice. Female Lewis rats were pur- 
chased  from The Jackson Laboratory (Bar Harbor, ME). 
Antigens and Antibodies.  Soluble HGG was purified from Cohn 
fraction II of human plasma by DEAE-cellulose chromatography 
as previously described (31). Anti-Thy 1.2 mAb was purchased from 
New England Nuclear (Boston, MA). Hybridoma cells secreting 
145-2Cll (hamster anti-mouse CD3e) were provided by Dr. J. A. 
Bluestone (University of Chicago, Chicago, IL) and the mAb was 
purified as described (32). The sources and purification procedures 
for anti-RL388Ag mAb (RL388), anti-mouse transferrin receptor 
(TfR) mAb (R17.217),  and polyclonal rat IgG were described pre- 
viously (32). PE-conjugated anti-B220 mAb and fluorescein (F1)- 
conjugated anti-Ia k mAb (specificity-2) were purchased from Phar- 
Mingen (San Diego, CA). The CTLA4Ig fusion protein and the 
purified human  mouse  chimeric mAb  L6 protein  were kindly 
provided by Dr. Peter Linsley (Bristol-Myers Squibb Pharmaceu- 
tical Research Institute, Seattle, WA). Hamster anti-CD28 (mAb 
37.51,  IgG2a) mAb was  kindly provided by Dr. James Allison 
(University of California at Berkeley, Berkeley, CA). Biotinylated 
anti-CD28 mAb was purchased from Caltag Laboratories (San Fran- 
cisco,  CA).  Fl-goat  F(ab')2 anti-human  IgG  (absorbed  against 
mouse  serum  proteins)  was  purchased from Jackson  Immuno- 
Research (West Grove,  PA). 
Th Clones and Lines.  The HGG-specific CD4 + Thl clones 
were developed,  maintained, and characterized as previously de- 
scribed (2). The Con A conditioned medium (CM) used in main- 
taining the clones and as a source of IL-2 in the experiments de- 
scribed  here,  was  prepared by collecting the  supernatant  from 
cultures of spleen cells from Lewis rats incubated at 106 cells/ml 
with 5/zg/ml Con A for 24 h. 
Preparation of Fixed APCs.  Splenocytes in RPMI-1640 medium 
(M. A. Bioproducts, Walkersville, MD) supplemented with 2 mM 
L-glutamine, 0.1 mM nonessential amino adds, 1 mM sodium pyru- 
vate, 100 U/m1 penicillin, 100/zg/ml streptomycin, 5  x  10 -s M 
2-ME, and 5% FCS (M. A. Bioproducts) were incubated at 2  x 
107/ml in medium alone, or with I mg/ml HGG for 3 h at 37~ 
The spleen cells were then washed in RPMI, passed over a Ficoll- 
Hypaque (FH) gradient to remove the dead cells, and fixed by using 
a modification of a previously described method (2). Briefly, the 
spleen cells were incubated in I ml of 0.15% paraformaldehyde in 
HBSS for 1 min at 37~  The reaction was stopped by adding 7 
ml of cold 0.5% glycylglycine. The fixed APCs were washed three 
times in medium before use. 
Primary Cultures  for lndudng Thl Cell Unresponsiveness.  Thl cells 
were harvested from culture 7-12 d after the last antigenic stimula- 
tion. They were passed over a FH gradient to remove old APCs, 
and incubated at 2.5  x  105 cells/ml in 0.2 ml medium consisting 
of i part Click's medium, I part supplemented RPMI-1640 medium, 
and 10% FCS. Also added to the primary cultures were untreated 
or activated B cells (5  x  106/ml) together with HGG. In some 
experiments, 5  x  106/ml HGG-pulsed fixed antigen presenting 
cells (FAPC) were added to the wells. The control cultures received 
B cells in the absence of HGG, or FAPC prepared in the absence 
of HGG. After incubation (48-72 h at 37~  the cells in these 
primary cultures were harvested, washed, passed over a FH gra- 
dient to remove the dead B cells or fixed APCs, and the Thl cells 
recultured in secondary cultures. In some experiments, the Thl 
cells were rested for an additional 1-3 d before being recultured 
in secondary cultures. 
Secondary Cultures  for Monitoring Tolerized Thl Cells.  Thl cells 
harvested  from  primary  cultures  were  recultured  at  5  x  10  4 
cells/well with 5  x  10S/well irradiated (3,000 rad of y-radiation) 
naive spleen cells and HGG, or with 10% Con A CM in plates 
(model 3596;  Costar Corp.,  Cambridge,  MA) in a 0.2-ml final 
volume. Cultures were incubated for 36 h at 37~  To measure 
DNA synthesis,  cultures were pulsed for 2 or 4 h with [3H]TdR, 
and  incorporated radioactivity was  determined by  scintillation 
counting. 
Immunofluorescent Staining and Flow Cytofluorometric Analysis. 
The formulation of staining medium and procedures for two-stage 
immunofluorescent (IF) staining were described previously (32). 
The mAb and polyclonal IgG were conjugated with F1 or PE as 
described  previously,  and were ultracentrifuged to eliminate ag- 
gregates (32). B cells from preincubation cultures were harvested 
at 36 h and viable B cells were isolated by FH density centrifuga- 
tion and two-color IF stained for B220 versus membrane RL388 
Ag, Ia  K, TfR, and B7. Non-B220 § cells (T cells or macrophages) 
were excluded  from analysis by gating on B220 + cells. Staining 
B7 was a two-step procedure involving an initial treatment with 
CTLA4Ig (5 #g/ml) or human mouse chimeric mAb L6 (5/~g/ml), 
followed by treatment with Fl-labeled  goat F(ab')2 anti-human 
IgG in the presence of 5% normal mouse serum. Th cells or anti- 
CD3-activated spleen cells were one color-stained for B7 expres- 
sion in a manner similar  to that used for B cells. Th cells were 
also IF stained for CD28 using biotinylated anti-CD28 mAb and 
PE-streptavidin. The stained cells were examined by flow cytofluo- 
rometry using a FACS  |  IV flow cytometer (Becton Dickinson & 
Co., Mountain View, CA), and optical arrangements and machine 
settings for the FACS  |  IV were previously described in detail (32). 
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tions histograms obtained from PE-gated viable cells were gener- 
ated as described (32). 
Preparation of Splenic B Cells.  Splenic B cells were isolated by 
double passage of T cell-depleted spleen cells over Sephadex G-10 
(Pharmacia,  Uppsala,  Sweden)  columns  as  described  (7).  The 
resulting spleen cell population was examined by cytofluorometric 
(FCF) analysis periodically and found to consist of >95% B220 § 
cells. The B cells were incubated at 5  x  106/ml for 24 or 48 h 
in medium alone, or in the presence of F(ab')2 goat anti-mouse 
IgM (Jackson ImmunoResearch; 10 #g/ml)  _+ 25/xg/ml LPS (Esch- 
erichia coli 0111:B4; Calbiochem-Novabiochem Corp., La Jolla, CA) 
or 4 ng/ml recombinant mouse IFN-y (Genentech, San Francisco, 
CA). After preincubation, the B cells were irradiated at 950 tad 
or treated with 50/~g/ml mitomycin C (Sigma Chemical Co., St. 
Louis,  MO) for 45 min at 37~  before use in primary cultures. 
Bioassays  for Monitoring B Cell Ag Presentation.  To examine the 
ability of B cells to present HGG to the Thl cells, B cells were 
added (5  x  106/m1 unless  otherwise specified) to 0.2-ml cultures 
of FH-purified Thl cells (2.5  x  10S/ml) in the absence or pres- 
ence of HGG (500 #g/ml unless otherwise specified). Proliferation 
was determined by measuring the amount of [3H[TdR. incorpo- 
rated during a 4-h pulse at 36 h of culture. To examine the ability 
of B cells to stimulate a MLR, the A/J-derived B cells (1.25  x 
106/ml)  were added to 0.2-ml cultures of C57BL/6 spleen  cells 
(1.25  x  106/ml).  Proliferation was determined by measuring the 
amount of [~H]TdR incorporated during a 4-h pulse on day 4. 
Results 
Ag-presenting Capacity of Activatecl B Cells.  This study to 
examine the tolerogenicity of activated B cells was begun by 
determining  whether  activated  B  cells  were  in  fact  more 
efficient than resting B  cells in presenting  HGG to HGG- 
specific Thl cells. Resting splenic B cells were left untreated 
or  treated  with  F(ab')2  goat  anti-mouse  IgM  alone or in 
combination with LPS or IFN-3, for 24 h. At this time, the 
B cells were tested for their ability to serve as APCs in two 
different assays, i.e., ability to present HGG to HGG-specific 
Thl cells, and ability to present allo-specific Ag in a MLR. 
As can be seen in Fig.  1, the most effective APCs in terms 
of presenting HGG to the Thl clones were untreated spleen 
cells. As shown previously (7), untreated resting B cells were 
very inefficient in presenting  HGG to the Thl  clones.  At 
high Ag concentrations, the ability of B cells to present HGG 
to Thl cells was enhanced slightly by treatment with anti-Ig 
or LPS,  Combinations  of anti-Ig  and LPS or INF-'y were 
no more effective than anti-Ig alone in stimulating B cell pre- 
sentation of HGG. In terms of stimulating a MLR, unsepa- 
rated spleen cells were again the most efficient APCs. Resting 
B cells were incapable of stimulating  a MLR.  In contrast, 
anti-Ig-treated B cells did stimulate a MLR. Combinations 
of anti-Ig and LPS or IFN-3' were also tested for their effects 
on B cell Ag presentation in the MLR,  and were found to 
be no more effective than anti-Ig alone. Taken together, these 
results illustrate that anti-Ig treatment enhances the ability 
of resting B cells to perform in a MLR, but has much less 
effect on the ability orB cells to present HGG to HGG-specific 
Thl  cells. 
Ability of  Activated B Cells to Present Ag in a Tolerogenic  Fashion 
to Thl Cells.  Even though anti-Ig-treated B cells were not 
efficient stimulators of HGG-specific Thl cell proliferation, 
it seemed likely that the ability of these B cells to stimulate 
a MLR was  due to expression of costimulatory molecules 
that would decrease, to at least some degree, the toleroge- 
nicity of the activated B cells. To test this possibility, resting 
splenic B cells were incubated for 24 h in medium alone, in 
the presence of anti-Ig alone, or in combination with LPS. 
The B  cells were then lightly irradiated  (950 tad)  and in- 
cubated in primary cultures with Thl cells in the presence 
or absence of HGG. After 3 d, the Thl cells from the pri- 
mary cultures were isolated and reincubated in secondary cul- 
tures stimulated with HGG and irradiated spleen cells as APCs, 
or with IL-2-containing Con A CM.  As shown previously, 
Thl cells from primary cultures containing HGG and resting 
B cells lost their ability to proliferate in Ag-stimulated sec- 
ondary cultures (Fig. 2).  In contrast to our expectation,  B 
cells treated with anti-Ig in the presence or absence of LPS 
also induced a dramatic decrease in the Ag-specific prolifera- 
tive capacity of Thl cells. Thl ceils incubated in primary cul- 
tures containing either resting or activated B cells but no HGG 
proliferated normally in the HGG-stimulated secondary cul- 
tures. All groups of Thl cells proliferated in a similar fashion 
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Figure 1.  Stimulatory capacity of B cells 
treated with anti-Ig for 24 h. Splenic B cells 
treated with anti-Ig and/or LPS or IFN-3' for 
24 h were compared with untreated splenic B 
cell and unseparated spleen  cells for their ability 
to  promote  HGG-specific proliferation of 
HGG-specific Thl clone JLB7, or for their 
ability to stimulate a primary MLR. In the ab- 
sence of HGG none of the APC populations 
induced Thl proliferation  >1,000 cpm. Similar 
results were obtained with two other HGG- 
specific Thl clones (12-11 and 4HE10). x 
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Figure 2.  B cells treated  with anti-Ig for 24 h still present  Ag in a tolero- 
genic fashion to Thl cells. Thl cells (clone 12-11) were incubated in pri- 
mary cultures with or without HGG together with B cells that were un- 
treated, or that had been treated for 24 h with anti-Ig and/or LPS. After 
3 d the Thl were isolated from the primary cultures and reincubated in 
secondary  cultures stimulated with HGG and APC. Additions to primary 
cultures: (ll) B cells; (El) B cells +  HGG; (0) anti-Ig-treated B cells; 
(O) anti-lg-treated B cells +  HGG; (A) LPS-treated B cells; (A) LPS- 
treated B cells + HGG; ( ~ ) anti-lg and LPS-treated  B cells; (O) anti-Ig 
and LPS-treated B cells +  HGG. Proliferation in the secondary cultures 
was measured. Very similar results were obtained in two other experi- 
ments using this as well as a second Thl clone (4HE10). 
in IL-2-containing secondary cultures. Based on these results, 
it appears  that incubation of B  cells with  anti-Ig for 24 h 
does not inhibit  the ability of the B  cells to present HGG 
in a  tolerogenic fashion  to Thl  cells. 
B cell tolerogenicity was dose dependent. A  summary of 
five experiments revealed that in the presence of 500/zg/ml 
HGG, Thl inactivation decreased from 78 to 66 to 49% when 
resting  B  cells  were  titrated  from  2.5  ￿  106/ml  to  5  ￿ 
105/ml to  105/ml,  respectively, in primary cultures of Thl 
cells. Experiments were also conducted in which Thl cells 
were exposed in primary cultures to 500/zg/ml  HGG and 
unseparated  spleen cells in concentrations  of 5  ￿  106/ml, 
106/ml,  or 2  ￿  10S/ml.  The Thl  cells were washed  after 
3  d,  rested for 3  d,  and  reincubated in Ag-stimulated  sec- 
ondary cultures.  The unseparated  spleen cells were unable 
to inactivate Thl cells by >16% at any concentration tested. 
Antigenicit 7 and Tolerogenicity of B  Cells Stimulated for 48 
Rather than 24 h.  It  has been reported  that  although  the 
Ag-presenting capacity of B  cells is enhanced after 24 h  in 
the presence of B cell stimulants, this enhanced capacity does 
not become resistant to chemical fixation or moderate doses 
of irradiation (3,000 rad) until after 48 h in the presence of 
the stimulants  (32,  33).  Therefore, it  seemed possible that 
the unaltered  tolerogenicity of B  cells stimulated  for 24 h 
with anti-Ig was due to the fact that some aspect of B cell 
Ag presentation only becomes evident after 48 h in culture. 
This possibility was  rendered unlikely when  it  was  found 
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Stimulatory capacity orB cells treated with anti-Ig for 48 h. 
Splenic B cells treated with anti-Ig in the presence or absence of LPS for 
48 h were compared with untreated splenic B cells and unseparated spleen 
cells for their ability to (A) promote HGG-specific  proliferation of the 
HGG-specific Thl clone 12-11, or (B) stimulate a primary MLR. 
that B cells treated with anti-Ig for 48 h were still inefficient 
stimulators of HGG-specific proliferation by Thl cells even 
though they were now as efficient as unseparated spleen cells 
in stimulating  a MLR (Fig. 3).  The inability of anti-Ig to 
stimulate B cells capable of stimulating HGG-specific prolifer- 
ation of Thl cells was not enhanced if LPS was used in con- 
junction with anti-Ig to pretreat the B cells.  In addition, ex- 
periments to test the tolerogenicity orb cells stimulated with 
anti-Ig for 48 h showed that these B cells did not lose their 
ability to present HGG in a tolerogenic fashion to Thl cells 
(Fig. 4). The anti-Ig-treated B cells were tolerogenic whether 
they were lightly irradiated or mitomycin C  treated before 
use as APCs. Thus, activation orb cells for 48 rather than 24 h 
did not  alter the tolerogenicity of the B  cells. 
Expression of  Accessory Molecules on Activated B Cells.  Ex- 
periments were conducted to determine the extent to which 
anti-Ig treatment enhanced B cell expression of accessory mol- 
ecules. Splenic B cells were incubated in medium alone, or 
in the presence of antiolg. After 36 h, the B cells were sub- 
jected to fluorescent staining and FCF analysis. The B220 § 
B cells were examined for their expression of B7 molecules, 
as well as other Ags (e.g., MHC class II molecules, RL388, 
and TfR) which can be used as markers for B cell activation. 
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Figure 4.  B cells treated with anti-Ig for 48 h still present Ag in a tolero- 
genie fashion to Thl cells. Thl cells (done JLB7) were incubated  in pri- 
mary cultures with or without HGG together with B cells which were 
untreated  or treated for 48 h with anti-Ig.  The B cells were either irradi- 
ated at 950 rad (A), or treated with mitomycin C  (/3) before use in the 
primary cultures. Thl cells isolated from the primary cultures were then 
reincubated in secondary cultures stimulated with HGG and splenic APC. 
Proliferation  in the secondary cultures was measured.  Thl cells exposed 
in primary cultures to HGG in the absence orb cells were not inactivated. 
In experiment B Thl cells exposed in primary cultures to HGG generated 
2,261, 3,647, and 8,879 cpm when stimulated  in secondary cultures with 
8, 40, and 200/~g/ml HGG, respectively. Additions  to primary cultures: 
(I) B cells; (El) B cells +  HGG; (O) anti-lg-treated B cells; (O) anti- 
Ig-treated B cells  +  HGG. 
For example, hyperexpression of Ia molecules is used as a 
marker for early B cell activation (30), whereas upregulation 
of RL388  and TfR are observed during early and late G1 
phase,  respectively (32).  Untreated resting B cells expressed 
moderate levels of MHC class II molecules, low levels of RL388 
Ag and TfR, and no detectable B7 (Fig.  5).  B cells treated 
with anti-Ig exhibited a large increase in their expression of 
Ia and RL388, and a definite shift in TfR expression. Most 
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Figure  5.  Expression  of activation  Ags on B  cells stimulated  with 
mitogens.  Splenic B cells were cultured for 36 h in medium alone, or with 
anti-Ig.  After incubation,  the cells were two-color stained for B220  and 
either la, RL388, or TfR (with rat IgG control) or B7 (with human IgG 
control),  and subjected to two-color FCF analysis. Shown are the F1 histo- 
grams  of B200 §  cells. 
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Figure  6.  Expression of CD28 and B7 on HGG-specific Th cells. Un- 
stimulated Thl and Th2 cells or anti-CD3-treated spleen cells were stained 
for CD28 or B7, and subjected to FCF analysis. Shown are the F1 histo- 
grams of the positively stained cells (dotted lines) compared to their Ig con- 
trols  (solid lines). 
importantly, B7 expression on anti-Ig-treated B cells (mean 
fluorescence intensity [MFI], 77.1) was greatly enhanced as 
compared to resting B cells (MFI, 7.2).  B7 expression was 
even higher (MFI, 243.8) on B cells treated with a combina- 
tion  of anti-Ig  and LPS  (data not  shown).  These results 
confirmed that treatment of B cells with anti-Ig in this system 
enhanced expression of several molecules, most notably B7, 
whose upregulation is associated  with B cell activation. 
Expression of CD28 and B7 on HGG-specific Th Clones.  The 
fact that activated B cells expressing high levels orB7 retained 
the ability to present Ag in a tolerogenic fashion to Thl cells 
could be explained if Thl cells lacked CD28 and were there- 
fore resistant to B7-mediated signaling. This possibility was 
examined and rejected after IF staining and FCF analysis of 
the Thl cells. Moderate to high levels of CD28 were expressed 
on all of the HGG-specific Thl clones examined (Fig.  6). 
In contrast, the Th2 clones examined expressed no detect- 
able CD28.  CD28 expression was not enhanced when the 
Th2 cells were stimulated for 36 h with anti-CD3 mAb (data 
not shown). Since B7 has been shown to be expressed on 
human T cell clones (34), the expression orB7 on the HGG- 
specific murine Th clones was also examined. The levels of 
253  Gilbert and Weigle B7 expressed by the different clones varied from moderate 
to low, and was not restricted to a particular Th cell subset. 
High levels of B7 were detected on spleen cells treated with 
anti-CD3  mAb.  Untreated  spleen cells expressed very low 
levels of B7 (data  not  shown). 
Confirming  Roles for B7 and CD28  in this System.  Even 
though CD28 was expressed on the HGG-specific Thl cells, 
and B7 was expressed on the activated B cells used in these 
experiments, it seemed possible that for some reason in this 
system B7 and CD28  did not mediate the same effects ob- 
served in other systems. Accordingly, experiments were con- 
ducted to test the functional roles of B7 and CD28  in our 
system. This included an examination of whether the increased 
B7 expression observed on B cells treated with mitogens was 
associated with the increased capacity of the B cells to serve 
as APCs.  The involvement of B7 in stimulating a MLR has 
been  demonstrated  by  others  (16,  35)  who  showed  that 
blocking B7 interaction with CD28 by the use of B7 mAb 
or CTLA4Ig inhibited the MLR. In the experiment described 
here, CTLA4Ig was titrated into cultures containing resting 
or anti-Ig-treated  splenic B  cells from A/J mice (H-2") as 
stimulator  cells  together with  C57B1/6  (H-2  b)  splenic re- 
sponder cells. As described in Fig. 3, anti-Ig-treated B cells, 
unlike resting B  cells, were efficient stimulators  of a MLR 
(Fig. 7). Addition of CTLA4Ig blocked, in a dose-dependent 
fashion, the ability of activated B cells to stimulate the MLR. 
The effect of CTLA4Ig on HGG-induced proliferation of the 
Thl cells was  also examined.  CTLA4Ig inhibited by 50% 
the modest ability of anti-Ig-treated B cells to promote HGG- 
specific proliferation (Fig. 8). The APC capacity of unsepa- 
rated spleen cells was also inhibited by CTLA4Ig. These results 
suggest that the activated B cells used in these experiments 
express functionally active B7 molecules, and that the HGG- 
specific Thl  cells are responsive to B7-mediated  signaling. 
As  confirmation  that  the  HGG-specific Thl  cells  were 
responsive to B7-CD28  interactions,  anti-CD28  mAb was 
tested for its ability to interfere with  the ability of HGG- 
pulsed fixed spleen cells to inactivate HGG-specific Thl cells. 
In three separate experiments,  Thl cells were incubated in 
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Figure 8.  Ability of CTLA4Ig to inhibit HGG-specific  Ag presenta- 
tion by activated B cells. APCs preincubated for 1 h in the presence (solid 
symbols) or absence (open symbols) of CTLA4Ig (10/zg/ml) were titrated 
to cultures of Thl cells (clone 12-11) and HGG. The APCs consisted of 
either unseparated spleen cells (squares), or resting (circles)  or anti-Ig-treated 
(triangles) B cells. 
the presence or absence of anti-CD28  mAb  together with 
HGG presented by either paraformaldehyde-fixed unseparated 
spleen cells (HGG-FAPC), resting B cells, or anti-Ig-treated 
B cells.  Control cultures of the Th cells received B cells in 
the absence of HGG,  or fixed spleen cells prepared in the 
absence of HGG (FAPC).  The Thl cells were subsequently 
isolated from the primary cultures  and reincubated in Ag- 
stimulated secondary cultures. As described previously, Thl 
cells exposed in primary cultures to HGG-FAPC, unlike Thl 
cells exposed to only FAPC,  lost their ability to proliferate 
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Figure 9.  Ability of anti-CD28 mAb to block HGG-specific  inactiva- 
tion of Thl cells. HGG-specific  Thl cells (clone 12-11) were incubated 
in primary cultures containing fixed spleen cells prepared in the absence 
ofHGG (FAPC) or the presence  ofHGG (HGG-FAPC) (Exp. I); resting 
B cells •  HGG (Exp. 2); or anti-Ig-treated B cells •  HC,  G (EXla 3). 
Anti-CD28 mAb was also added to some primary cultures. Additions to 
primary cultures: (t~) APC; (m) APC + HGG; ([]) APC + anti-CD28; 
([]) APC  +  HGG +  anti-CD28. Thl cells isolated from the primary 
cultures were subsequently reincubated in secondary  cultures stimulated 
with HGG and APC. Proliferation  was measured  in the secondary  cultures. 
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specific inactivation induced by HGG-FAPC was prevented 
if anti-CD28 mAb was also present in the primary cultures. 
Similarly,  anti-CD28 mAb inhibited Thl cell anergy induced 
by resting or anti-Ig-treated  B cells.  Taken  together,  these 
results show that  at least some of the functional effects of 
CD28 and B7 described in other systems can be demonstrated 
in the present  system. 
Discussion 
It seemed likely that the previously documented ability of 
resting B cells  to present  Ag to Thl  cells in a tolerogenic 
rather  than  stimulatory fashion (7)  was due to a lack of B 
cell costimulatory molecules, notably B7. However, in con- 
trast to expectations, treatments that were shown to enhance 
certain aspects of B cell Ag presentation,  as well as B cell 
expression of accessory molecules including B7, were found 
here to have no effect on B cell tolerogenicity. Similar to un- 
treated resting B ceils, anti-Ig-activated B cells presented Ag 
to Thl cells in a manner that induced Ag-specific prolifera- 
tive inactivation.  There is evidence to suggest that a similar 
phenomenon can also occur in vivo. Fuchs and Matzinger 
(10) showed that LPS-treated B cells from male mice were 
similar to resting B cells in their capacity to induce H-Y-specific 
inactivation  when injected into female mice. This inactiva- 
tion, which was demonstrated as a decrease in cytotoxic T 
cell responses and prolonged skin graft survival, was not in- 
duced if dendritic cells rather than B cells were injected. In 
potential contrast to our findings,  it was shown in another 
study (8) that although divalent F(ab')2 fragments of rabbit 
anti-mouse IgD did induce unresponsiveness to nonimmune 
rabbit  Ig in mice,  the F(ab')2  fragments were less effective 
than monovalent fragments in inducing this inactivation. The 
authors suggested that the F(ab')2 fragments of anti-mouse 
Ig activated the B ceils by crosslinking surface Ig, and thereby 
reduced the tolerogenicity of resting B cells.  However, the 
authors could not rule out the perhaps more likely possibility 
that the divalent fragments formed complexes with circulating 
IgD that were then captured and presented by professional 
APCs rather  than B cells.  In other studies, it was reported 
that  even resting  B cells  possessed more costimulatory ca- 
pacity for Thl cells than described here (33), and could in- 
terfere with Thl cell tolerance induction when added to cul- 
tures of Thl ceils in the presence of peptide and fixed spleen 
cells (36). The apparent disparity between these findings and 
our and others' results showing that resting B cells are poor 
costimulators for Thl cells (3, 7), could be explained if cer- 
tain Thl clones have fewer requirements  for costimulatory 
activity. Along these lines,  it was shown subsequently that 
the  Thl  clone A.E7,  which  was featured  in  both  studies 
describing efficient B cell APC activity for Thl cells, differed 
from other Thl  clones tested in that  the A.E7 cells could 
bypass costimulator requirements and proliferate to immobi- 
lized anti-CD3 in the absence of accessory cells (37). There- 
fore, the results obtained using the A.E7 clone may not reflect 
the responses of other Thl clones, or naive T cells, with more 
stringent  costimulator  requirements.  Taken  together,  the 
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reported results of others are not inconsistent with our finding 
that resting B cells can present Ag in a tolerogenic fashion 
to Thl cells, and that  activation of the B cells does not in- 
hibit  this B  cell  activity. 
The ability of anti-Ig-treated  B cells  to present Ag in a 
tolerogenic fashion to Thl cells in the present system cannot 
be attributed to the fact that for some reason these B cells 
were not activated. Although B cell treatment with anti-Ig 
did not reverse B cell tolerogenicity, it did enhance certain 
aspects of B cell Ag presentation.  Unlike resting B cells, B 
cells incubated with anti-Ig mAb for 24 or 48 h, efficiently 
stimulated  a MLR, and were somewhat  more effective in 
stimulating HGG-induced proliferation of HGG-specific Thl 
cells. The activation state of the stimulated, but still tolero- 
genic B cells was further demonstrated by the enhanced ex- 
pression of MHC class  II molecules,  RL388 and TfR,  on 
these B cells. In addition, unlike untreated splenic B cells which 
exhibited undetectable levels orB7, splenic B cells treated with 
anti-Ig expressed high levels of B7. The functional relevance 
of the B7 expressed on the activated B cells used here was 
demonstrated by showing that  the ability of the mitogen- 
activated B cells to stimulate a MLR or promote Ag-specific 
Thl proliferation was inhibited by the addition of CTLA4Ig. 
CTLA4Ig, a soluble fusion protein incorporating the extracel- 
lular  domain  of CTLA-4 with  the CH2 and CH3 region 
of human  Ig/C3,1 blocks B7 activity (35).  Whereas it has 
not been reported that CTLA4Ig binds to Fcgs on murine 
APCs,  the possibility exists that  CTLA4Ig blocks HGG- 
specific Ag presentation by inhibiting FcR-mediated uptake 
of HGG by APCs rather than by blocking B7 expression on 
APCs.  Such a mechanism is, however, unlikely,  and would 
not account for CTLA4Ig-mediated  inhibition  of a MLR. 
Thus, the results suggest that the levels of B7 expressed on 
the anti-Ig-stimulated B cells used in these experiments were 
functionally effective. It should be mentioned that even though 
anti-Ig treatment of B cells can stimulate expression of acces- 
sory molecules and DNA synthesis by these cells (32, 38), 
it can also make the B cells refractory to further stimulation 
(39).  The anti-Ig-treated  B cells used here were not tested 
for their subsequent proliferative capacity. However, even if 
the B cells were ultimately unresponsive,  the results show 
that  B cells  that  express B7, and are at least partially acti- 
vated,  can tolerize Thl  cells. 
The tolerogenicity of activated B cells cannot be attrib- 
uted to the fact that  the Thl  cells used in this study were 
incapable of CD28-mediated signaling. All the Thl cells used 
in the experiments were found to express CD28. The associ- 
ation  of CD28  expression  with  Thl  clones  fits  in  with 
the  previous  observation  that  mitogen-stimulated  human 
CD28 + T  cells make only those lymphokines produced by 
Thl cells (40). The functional competence of the CD28 ex- 
pressed by the Thl cells in this study was demonstrated when 
anti-CD28  mAb was shown to inhibit  tolerance induction 
in HGG-specific Thl cells exposed to Ag-pulsed fixed APCs 
or Ag-presenting B cells.  This finding is similar to that  of 
Harding et al.  (18) who showed that  anti-CD28  mAb in- 
hibited T  cell inactivation  when  added to cultures  of Thl 
cells specific for )x repressor protein and Ag-pulsed fixed APCs. Taken together,  the results presented here suggest that  the 
Thl clones used in this study can be activated through CD28. 
Although the HGG-specific Thl cells appear to have func- 
tionally active receptors for B7, upregulation of B7 expres- 
sion on anti-Ig-treated B cells was not sufficient to alter the 
tolerogenicity of these B cells for Thl cells. This observation 
was somewhat surprising in view of the reported correlation 
between B7 expression and APC costimulatory activity. The 
ability of B cell tumor lines to stimulate  a MLR has been 
shown  to  correlate  with  expression  of B7  (41),  and  B7- 
transfected CHO cells, unlike untranslated cells, can costimu- 
late a MLR,  as well as mitogen-induced  and Ag-specific T 
cell proliferation (42). In addition, blocking B7-mediated sig- 
naling appears to inhibit APC immunogenicity and enhance 
APC  tolerogenicity.  For example,  it  has  been shown that 
CTLA4Ig treatment induced long-term tolerance to human 
pancreatic  islet cells in mice (43),  and caused T  cell hypo- 
responsiveness to alloantigens  in a human mixed leukocyte 
culture (44). 
Although the studies described above argue convincingly 
that blocking B7-mediated signaling inhibits the costimula- 
tory activity of B7-expressing APCs, and enables these APCs 
to present Ag in a tolerogenic fashion to CD4 + T cells, the 
results of our study suggest that the reverse may not neces- 
sarily be true.  It appears that  increasing  the B7 expression 
on tolerogenic APCs does not necessarily enable these APCs 
to present Ag in an immunogenic fashion to CD4 + T cells. 
Similar to our fndings using activated B cells,  Freedman et 
al.,  (45) found that  IFN-y treatment  did not  enhance  the 
costimulatory  capacity  of the  monocytes,  even  though  it 
significantly  enhanced  B7  expression  on  monocytes.  The 
authors proposed that  the contrast between the costimula- 
tory activity of B7-expressing monocytes and the costimula- 
tory capacity of B7-transfected cells was linked to a quantita- 
tive difference in B7 expression. It has been reported that CD28 
can induce two different levels of costimulation,  one that is 
mediated by a pathway independent of the TCR and requires 
minimal  CD28 receptor oligomerization,  and one that  re- 
quires a high degree of receptor crosslinking  and delivers  a 
more potent primary signal to the T cells (for review see ref- 
erence 15). If B7 is present on the APCs in sufficient quanti- 
ties (e.g., on B7-transfected APCs) to induce extensive CD28 
crosslinking,  this costimulatory molecule may be all that is 
required for Thl  cell activation.  On the other hand,  it ap- 
pears that under more physiological conditions,  the level of 
B7 expression on activated B cells is not  sufficient to fully 
costimulate Ag-specific proliferation of the Ag-specific Thl 
cells. Presentation of Ag to Ag-specific Thl cells may have 
more stringent  requirements for costimulatory signals  than 
other bioassays such as a primary MLR. Primary MLRs are 
often, as is the case in this study, performed in the presence 
of responder adherent cells which may provide accessory cell 
signals that amplify or even costimulate the signals provided 
by the alloantigen-bearing B cells. In addition, both Thl and 
Th2 CD4 § T cells, which have been shown to have different 
costimulator requirements (3), may participate in the MLR 
responder  population. 
The results from this study can be explained if Thl  cell 
activation requires a certain cumulative level of costimula- 
tory  signals  in  addition  to  TCR  ligation.  This  level  of 
costimulatory activity may not be attainable on B cells. Two 
possible exceptions must be mentioned. First, Thl cells which 
for some reason have less stringent costimulator requirements 
than  the Thl  cells used here,  may be stimulated by B cell 
APCs.  Second,  it is possible that  unlike  the activating re- 
gimes used in this study, certain B cell stimulatory treatments 
(e.g.,  interaction  with Ag-activated Th2 cells)  may induce 
more potent B cell costimulators, and turn B cells into efficient 
APCs for Thl cells. Bearing in mind these two possible caveats, 
it is possible to propose a model in which physiological levels 
of B7 on APCs are required but not sufficient for Ag-induced 
Thl cell activation. This would mean that blocking B7 would 
inhibit Thl cell activation and thus lead to tolerance induc- 
tion, hut that expression of B7 at physiological levels, in the 
absence of other costimulatory signal(s), would not lead to 
complete Thl cell activation. Thl cell activation may require 
an additional,  non-B7 costimulator signal,  such as has been 
implicated in Thl  stimulation by brain microvessel smooth 
muscle cells/pericytes (46). 
The role of B7 in stimulating  Th2 activation is unclear. 
The Th2  cells tested in  this  study did not express CD28, 
eliminating  this means of B7-mediated signaling.  However, 
it is possible that these Th2 cells have lost CD28 expression 
as a result of long-term  tissue culture.  Alternatively,  these 
Th2 cells may express the other ligand for B7, CTLA4, and 
are therefore still susceptible to B7-mediated signaling.  It is 
also possible that Th2 cells, which can be activated to pro- 
duce IL-4 by TCR crosslinking alone (47), may not require 
signaling from B7 and/or other putative costimulatory mol- 
ecules.  A  lack of costimulatory requirements  by Th2 cells 
would explain why resting B cells, which can crosslink the 
TCR,  but appear to lack costimulator  molecules,  are  effi- 
cient APCs for Ag-induced Th2 cell but not Thl cell pro- 
liferation  (3,  7). 
The authors wish to thank Dr. David Ernst (The Scripps Research Institute)  for providing many of the 
antibodies used in the FCF analysis, and Ms. Alica Palestini for her excellent secretarial assistance. 
This work was supported  by grant  AI-15761 from the National  Institutes  of Health. 
Address correspondence to Dr. Kathleen M. Gilbert,  Department of Immunology/IMM9, The Scripps 
Research Institute,  10666 North Torrey Pines Road, La Jolla,  CA 92037. 
Received for publication 7June 1993 and in revised  form 23 September 1993. 
256  Tolerogenicity  of Resting and Activated B Cells Note added in proof It has recently been shown that activated B cells express CTLA-4 counter-receptors 
which are distinct from the molecule termed B7 (48, 49). Since these CTLA-4 counter-receptors are appar- 
ently expressed by 48 h after B cell activation, a time at which we show that activated B cells are tolero- 
genie, it seems unlikely that expression of any of the family of B7 molecules is sufficient to interfere with 
B cell tolerogenicity in our system. 
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